文献速递炎症性肠病

长期皮质类固醇治疗相比抗肿瘤坏死因子-α治疗在炎症性肠病中死亡率升高

Increased Mortality Rates With Prolonged Corticosteroid Therapy When Compared With Antitumor Necrosis Factor-α-Directed Therapy for Inflammatory Bowel Disease.
PubMed 文献 · Am J Gastroenterol · 2018-01-16

该回顾性队列研究基于2001至2013年美国Medicaid和Medicare受益者,比较炎症性肠病(IBD)中长期皮质类固醇使用与新启用抗肿瘤坏死因子-α(抗TNF)治疗的死亡率。结果显示,克罗恩病(CD)患者抗TNF治疗的全因死亡率显著低于长期激素治疗(OR 0.78,95%CI 0.65-0.93),而溃疡性结肠炎(UC)患者两组死亡率无显著差异(OR 0.87,95%CI 0.63-1.22)。

要点

  • CD患者中,抗TNF治疗较长期激素治疗的全因死亡率显著降低(OR 0.78,95%CI 0.65-0.93)。
  • UC患者中,抗TNF治疗与长期激素治疗的全因死亡率无显著差异(OR 0.87,95%CI 0.63-1.22)。
  • CD队列中,抗TNF治疗与较低的主要不良心血管事件(OR 0.68)和髋部骨折(OR 0.54)风险相关。

核心结论

  • 与长期皮质类固醇暴露相比,抗TNF药物使用与CD患者死亡率降低相关,可能由主要不良心血管事件和髋部骨折发生率较低解释。

研究设计与样本

  • 回顾性队列研究,纳入2001至2013年Medicaid和Medicare受益者中IBD患者,暴露定义为12个月内泼尼松等效剂量>3,000 mg或新启用抗TNF治疗,均作为时间更新暴露。
  • CD队列中7,694例进入长期皮质类固醇组,1,879例进入新抗TNF组;UC队列中3,224例进入长期皮质类固醇组,459例进入新抗TNF组。
  • 主要结局为全因死亡率,次要结局为常见死因,采用边际结构模型计算抗TNF相对于皮质类固醇的OR和95%CI。

主要发现

  • CD患者中,抗TNF治疗组死亡率为21.4/1000人年,长期皮质类固醇组为30.1/1000人年,OR 0.78(95%CI 0.65-0.93)。
  • UC患者中,抗TNF治疗组死亡率为23.0/1000人年,长期皮质类固醇组为30.9/1000人年,OR 0.87(95%CI 0.63-1.22)。
  • CD队列中,抗TNF治疗与较低的主要不良心血管事件风险相关(OR 0.68,95%CI 0.55-0.85)。
  • CD队列中,抗TNF治疗与较低的髋部骨折风险相关(OR 0.54,95%CI 0.34-0.83)。

关键数值与推荐

  • 原文未报告指南或共识推荐条款。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Crohn's disease (CD) and ulcerative colitis (UC) are inflammatory bowel diseases (IBD) that compromise quality of life and may increase mortality. This study compared the mortality risk with prolonged corticosteroid use vs. antitumor necrosis factor-α (anti-TNF) drugs in IBD. METHODS: A retrospective cohort study was conducted among Medicaid and Medicare beneficiaries from 2001 to 2013 with IBD prescribed either >3,000 mg of prednisone or equivalent within a 12-month period or new initiation of anti-TNF therapy, each treated as time-updating exposures. The primary outcome was all-cause mortality. Secondary outcomes included common causes of death. Marginal structural models were used to determine odds ratios (ORs) and 95% confidence intervals (CIs) for anti-TNF use relative to corticosteroids. RESULTS: Among patients with CD, 7,694 entered the cohort as prolonged corticosteroid users and 1,879 as new anti-TNF users. Among patients with UC, 3,224 and 459 entered the cohort as prolonged CS users and new anti-TNF users, respectively. The risk of death was statistically significantly lower in patients treated with anti-TNF therapy for CD (21.4 vs. 30.1 per 1,000 person-years, OR 0.78, 0.65-0.93) but not for UC (23.0 vs. 30.9 per 1,000 person-years, OR 0.87, 0.63-1.22). Among the CD cohort, anti-TNF therapy was also associated with lower rates of major adverse cardiovascular events (OR 0.68, 0.55-0.85) and hip fracture (OR 0.54, 0.34-0.83). CONCLUSIONS: Compared with prolonged corticosteroid exposure, anti-TNF drug use was associated with reduced mortality in patients with CD that may be explained by lower rates of major adverse cardiovascular events and hip fracture.

来源:Am J Gastroenterol,查看原文。版权归原作者所有。

引用

  1. Lewis JD, Scott FI, Brensinger CM, et al. Increased Mortality Rates With Prolonged Corticosteroid Therapy When Compared With Antitumor Necrosis Factor-α-Directed Therapy for Inflammatory Bowel Disease. Am J Gastroenterol. 2018. PMID: 29336432. doi:10.1038/ajg.2017.479

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。